As a novel therapy target, hK2 has several possible advantages: it is highly restricted, although not completely, to prostatic tissue and it has a possibly higher expression in some patients following EBRT [41] and a seemingly retained expression in the different clinical phases of PCa. This evidence concerns the gene HK2 and posterior cortical atrophy.